Cargando…

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography

Soluble urokinase plasminogen activation receptor (suPAR) is risk factor for kidney disease and biomarker for cardiovascular outcomes but long term longitudinal analyses in a large European cohort have not been perfomed. To hus, we studied suPAR in participants of the Ludwigshafen Risk and Cardiovas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sommerer, Claudia, Zeier, Martin, Morath, Christian, Reiser, Jochen, Scharnagl, Hubert, Stojakovic, Tatjana, Delgado, Graciela E., März, Winfried, Kleber, Marcus E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346054/ https://www.ncbi.nlm.nih.gov/pubmed/30679668 http://dx.doi.org/10.1038/s41598-018-36960-6

Ejemplares similares

Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients
por: Morath, Christian, et al.
Publicado: (2022)

Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD
por: Sommerer, Claudia, et al.
Publicado: (2023)

Independent Effects of Kidney Function and Cholesterol Efflux on Cardiovascular Mortality
por: Ritsch, Andreas, et al.
Publicado: (2022)

Telomere length, vitamin B12 and mortality in persons undergoing coronary angiography: the Ludwigshafen risk and cardiovascular health study
por: Pusceddu, Irene, et al.
Publicado: (2019)

Neutrophil gelatinase-associated lipocalin levels are U-shaped in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study—Impact for mortality
por: Woitas, Rainer P., et al.
Publicado: (2017)

Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study
por: Nusshag, Christian, et al.
Publicado: (2019)

Cholesterol Efflux Capacity and Cardiovascular Disease: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study
por: Ritsch, Andreas, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients
por: Torino, Claudia, et al.
Publicado: (2018)

Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients
por: Manshad, Ahmad S., et al.
Publicado: (2022)

Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography—The LURIC study
por: Scharnagl, Hubert, et al.
Publicado: (2014)

Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
por: Katzmann, Julius L., et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
por: Rovina, Nikoletta, et al.
Publicado: (2020)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
por: Hindy, George, et al.
Publicado: (2022)

Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus
por: Dande, Ranadheer R., et al.
Publicado: (2017)

Gender- and subgroup-specific sensitivity analysis of alcohol consumption and mortality in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study
por: Moissl, Angela P., et al.
Publicado: (2022)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor level in individuals of advanced age
por: Wlazel, Rafal N., et al.
Publicado: (2020)

Combined Use of Serum Uromodulin and eGFR to Estimate Mortality Risk
por: Yazdani, Babak, et al.
Publicado: (2021)

The association of high-normal international-normalized-ratio (INR) with mortality in patients referred for coronary angiography
por: Delgado, Graciela E., et al.
Publicado: (2019)

Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
por: Wittenhagen, Per, et al.
Publicado: (2011)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
por: Erkut, Nergiz, et al.
Publicado: (2016)

Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2018)

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
por: Böcskei, Renáta M., et al.
Publicado: (2019)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea
por: Bocskei, Renata Marietta, et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
por: Mehta, Anurag, et al.
Publicado: (2020)

Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin
por: Hladunewich, Michelle A., et al.
Publicado: (2021)

Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High‐Sensitivity C‐Reactive Protein
por: Hayek, Salim S., et al.
Publicado: (2018)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
por: Ichihara, Noboru, et al.
Publicado: (2017)

Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity
por: Raff, Hershel, et al.
Publicado: (2020)

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease
por: Ahmed, Reem M., et al.
Publicado: (2019)

Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
por: Velissaris, Dimitrios, et al.
Publicado: (2021)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
por: El‑Patal, Mohamed Abd‑Ellatif, et al.
Publicado: (2022)

Comparison of Two Nuclear Magnetic Resonance Spectroscopy Methods for the Measurement of Lipoprotein Particle Concentrations
por: Rief, Martin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_snc1f7e3v8i0no9if6fnnh4u65